相关实验视频
Updated: May 2, 2026
06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 24, 2010
16.8K
针对阿尔茨海默病的基于多式融合的深度学习的综述
Rong Zhang1, Jinhua Sheng1, Qiao Zhang2
1School of Computer Science and Technology, Hangzhou Dianzi University, Hangzhou, Zhejiang 310018, China; Key Laboratory of Intelligent Image Analysis for Sensory and Cognitive Health, Ministry of Industry and Information Technology of P. R. China, Hangzhou, Zhejiang 310018, China.
Neuroscience
|April 26, 2025
概括
这篇评论探讨了MRI和PET扫描用于阿尔茨海默氏症 (AD) 诊断的深度学习融合. 进步的多式成像技术有助于对这种神经退行性疾病的早期发现和干预策略.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 神经学 神经学
背景情况:
- 阿尔茨海默病 (AD) 是一种主要的神经退行性疾病,导致认知能力下降.
- 早期诊断和评估对于管理AD进展至关重要.
- 多模式成像,结合MRI和PET,为AD提供了互补的结构和代谢见解.
研究的目的:
- 系统地审查基于深度学习的MRI和PET图像的多式融合在AD研究的最新进展.
- 专注于2021年至2025年间发表的研究.
- 为MRI和PET多式融合研究人员提供指导,用于早期AD诊断.
主要方法:
- 数据预处理和特征提取与AD相关的成像数据.
- 性能指标和多式联接技术的总结.
- 探索深度学习模型和多式联络融合任务的变体.
主要成果:
- 最近的深度学习技术使得MRI和PET数据在阿尔茨海默病研究中能够有效地融合.
- 在多式联络融合任务中,各种深度学习模型显示出前景.
- 主要挑战包括数据稀缺性,不平衡性和异质性.
结论:
- 基于深度学习的MRI和PET的多式融合显示了促进早期AD诊断的巨大潜力.
- 解决数据异质性等挑战对于未来的进步至关重要.
- 本综述为改善AD干预提供了解决方案和未来研究方向的见解.
相关概念视频
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21